Company Castle Biosciences, Inc.

Equities

CSTL

US14843C1053

Medical Equipment, Supplies & Distribution

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for Castle Biosciences, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Diagnostic & Testing Substances

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
21.53 ^USD	+5.85%		+9.79%	-0.23%

08/04	Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing	MT
04/04	Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress	CI

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.

Number of employees: 610

USD in Million	2022	Weight	2023	Weight	Delta
Dermatologic 83.4 %	125	91.1 %	183	83.4 %	+46.92%
Non-Dermatologic 16.6 %	12	8.9 %	36	16.6 %	+197.74%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	137	100.0 %	220	100.0 %	+60.38%

Managers	Title	Age	Since
Derek Maetzold FOU	Founder	62	01/07/01
Franklin Stokes DFI	Director of Finance/CFO	54	01/17/01
Johnson Clare CTO	Chief Tech/Sci/R&D Officer	-	01/21/01
Chris Otte CTO	Chief Tech/Sci/R&D Officer	-	-
Matthew Goldberg CTO	Chief Tech/Sci/R&D Officer	-	01/20/01
Robert W. Cook CTO	Chief Tech/Sci/R&D Officer	52	01/11/01
Kristen Oelschlager COO	Chief Operating Officer	56	01/08/01
Camilla Zuckero IRC	Investor Relations Contact	-	01/19/01
Kevin Doman SAM	Sales & Marketing	-	01/22/01
Keli Greenberg HRO	Human Resources Officer	-	01/20/01

Members of the board	Title	Age	Since
Derek Maetzold FOU	Founder	62	01/07/01
Daniel Bradbury CHM	Chairman	62	01/12/01
G. Cole BRD	Director/Board Member	68	06/18/06
Tiffany Olson BRD	Director/Board Member	64	08/21/08
Mara Aspinall BRD	Director/Board Member	61	24/15/24
Kimberlee Caple BRD	Director/Board Member	62	16/21/16
Ellen Goldberg BRD	Director/Board Member	50	16/21/16
Miles Harrison BRD	Director/Board Member	59	01/20/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	27,587,062	26,749,980 ( 96.97 %)	0	96.97 %

Name	Equities	%	Valuation
Wasatch Advisors, Inc. 9.294 %	2,551,088	9.294 %	57 M $
Granahan Investment Management, LLC 7.892 %	2,166,471	7.892 %	48 M $
BlackRock Advisors LLC 7.607 %	2,088,218	7.607 %	46 M $
Principal Global Investors LLC 5.777 %	1,585,673	5.777 %	35 M $
Vanguard Fiduciary Trust Co. 5.324 %	1,461,481	5.324 %	32 M $
Bellevue Asset Management AG 4.490 %	1,232,378	4.490 %	27 M $
Deerfield Management Co. LP (Private Equity) 3.517 %	965,428	3.517 %	21 M $
Portolan Capital Management LLC 2.654 %	728,653	2.654 %	16 M $
Millennium Management LLC 2.610 %	716,350	2.610 %	16 M $
Dimensional Fund Advisors LP 2.419 %	663,882	2.419 %	15 M $

Castle Biosciences, Inc.

505 South Friendswood Drive Suite 401

77546, Friendswood

http://www.castlebiosciences.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.53 USD

Average target price

33.11 USD

Spread / Average Target

+53.79%

Consensus

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
CASTLE BIOSCIENCES, INC.	-0.23%	594M
BIOMÉRIEUX	+0.70%	12.95B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-7.57%	7.84B
DIASORIN S.P.A.	+1.46%	5.5B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.93%	4.61B
LANTHEUS HOLDINGS, INC.	+8.48%	4.61B
10X GENOMICS, INC.	-49.25%	3.4B
ANDON HEALTH CO., LTD.	+9.21%	2.66B
VITROLIFE AB	-14.59%	2.08B
MYRIAD GENETICS, INC.	+3.45%	1.79B

Diagnostic & Testing Substances